Financial support

If your healthcare provider has already determined that a Gilead treatment is right for you, then the Gilead Advancing Access® program is committed to helping you afford your medication every step of the way.

Whether you are insured, uninsured, or underinsured, Advancing Access is available to help you:

advancing-access
  • Lower your co-pay* and find other co-pay support, if eligible
  • Find and get financial support if you have government insurance
  • Find and get financial support if you are uninsured

*See specific terms and conditions at: www.GileadAdvancingAccess.com.

Insurance support

IMPORTANT SAFETY INFORMATION (continued)

Who should not take BIKTARVY?

Do not take BIKTARVY if you take:

  • dofetilide
  • rifampin
  • any other medicines to treat HIV-1

Advancing Access is also available to help you obtain coverage for your Gilead medication, including support to help you:

  • Identify and confirm coverage and benefits
  • When your insurance or coverage changes
  • When you need assistance understanding insurance

Find out more about the Gilead Advancing Access program

Enroll at GileadAdvancingAccess.com by downloading and completing the enrollment form today. Or you can call ‍‍1-800-226-2056 ‍1-800-226-2056 M–F, 9am–8pm ET.

sign-upGileadAdvancingAccess.com

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about BIKTARVY?

BIKTARVY may cause serious side effects:

  • Worsening of hepatitis B (HBV) infection. If you have both HIV-1 and HBV and stop taking BIKTARVY, your HBV may suddenly get worse. Do not stop taking BIKTARVY without first talking to your healthcare provider, as they will need to monitor your health.

Who should not take BIKTARVY?

Do not take BIKTARVY if you take:

  • dofetilide
  • rifampin
  • any other medicines to treat HIV-1

What are the other possible side effects of BIKTARVY?

Serious side effects of BIKTARVY may also include:

  • Changes in your immune system. Your immune system may get stronger and begin to fight infections. Tell your healthcare provider if you have any new symptoms after you start taking BIKTARVY.
  • Kidney problems, including kidney failure. Your healthcare provider should do blood and urine tests to check your kidneys. If you develop new or worse kidney problems, they may tell you to stop taking BIKTARVY.
  • Too much lactic acid in your blood (lactic acidosis), which is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat.
  • Severe liver problems, which in rare cases can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark “tea-colored” urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.

The most common side effects of BIKTARVY in clinical studies were diarrhea (6%), nausea (5%), and headache (5%). Tell your healthcare provider if you have any side effects that bother you or don’t go away.

What should I tell my healthcare provider before taking BIKTARVY?

  • All your health problems. Be sure to tell your healthcare provider if you have or have had any kidney or liver problems, including hepatitis virus infection.
  • All the medicines you take, including prescription and over-the-counter medicines, antacids, laxatives, vitamins, and herbal supplements. BIKTARVY and other medicines may affect each other. Keep a list of all your medicines and show it to your healthcare provider and pharmacist, and ask if it is safe to take BIKTARVY with all of your other medicines.
  • If you are pregnant or plan to become pregnant. It is not known if BIKTARVY can harm your unborn baby. Tell your healthcare provider if you become pregnant while taking BIKTARVY.
  • If you are breastfeeding (nursing) or plan to breastfeed. Do not breastfeed. HIV-1 can be passed to the baby in breast milk.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call ‍1‑800‑FDA‑10881‑800‑FDA‑1088.

You are now leaving BIKTARVY.com.

By following this link, you are now leaving BIKTARVY.com. This site is not controlled by Gilead Sciences, Inc. Gilead Sciences, Inc. is not responsible for the site's content or your use of the site.

You are now leaving BIKTARVY.com

Would you like to continue?